NVO vs. CPH.TO
NVO (Novo Nordisk A/S) and CPH.TO (Cipher Pharmaceuticals Inc.) are both stocks. Both are in the Healthcare sector — NVO in Drug Manufacturers - General, CPH.TO in Drug Manufacturers - Specialty & Generic. Over the past 10 years, NVO returned 6.20%/yr vs 7.91%/yr for CPH.TO. At a 0.11 correlation, their price movements are largely independent.
Performance
NVO vs. CPH.TO - Performance Comparison
Loading charts...
Different Trading Currencies
NVO is traded in USD, while CPH.TO is traded in CAD. To make them comparable, the CPH.TO values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, NVO achieves a -16.56% return, which is significantly lower than CPH.TO's 10.08% return. Over the past 10 years, NVO has underperformed CPH.TO with an annualized return of 6.20%, while CPH.TO has yielded a comparatively higher 7.91% annualized return.
NVO
- 1D
- -4.52%
- 1M
- -10.96%
- YTD
- -16.56%
- 6M
- -9.23%
- 1Y
- -42.47%
- 3Y*
- -17.53%
- 5Y*
- 1.78%
- 10Y*
- 6.20%
CPH.TO
- 1D
- -0.04%
- 1M
- -16.23%
- YTD
- 10.08%
- 6M
- 14.24%
- 1Y
- 24.86%
- 3Y*
- 62.35%
- 5Y*
- 56.53%
- 10Y*
- 7.91%
NVO vs. CPH.TO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | -16.56% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
CPH.TO Cipher Pharmaceuticals Inc. | 10.08% | 10.20% | 138.31% | 47.79% | 104.02% | 90.42% | -36.49% | -8.51% | -67.81% | 7.26% |
Correlation
The correlation between NVO and CPH.TO is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.10 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Jul 5, 2006 | 0.11 |
Fundamentals
NVO:
$182.49B
CPH.TO:
CA$435.58M
NVO:
$27.42
CPH.TO:
CA$1.19
NVO:
1.50
CPH.TO:
14.22
NVO:
0.06
CPH.TO:
0.17
NVO:
0.56
CPH.TO:
8.65
NVO:
0.90
CPH.TO:
3.28
NVO:
$327.80B
CPH.TO:
CA$50.92M
NVO:
$268.30B
CPH.TO:
CA$37.95M
NVO:
$181.54B
CPH.TO:
CA$25.12M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. CPH.TO — Risk / Return Rank
NVO
CPH.TO
NVO vs. CPH.TO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Cipher Pharmaceuticals Inc. (CPH.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NVO | CPH.TO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.41 | ||
| Sortino ratioReturn per unit of downside risk | -2.32 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 1.15 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | -0.77 | 1.03 | -1.80 |
| Martin ratioReturn relative to average drawdown | -1.14 | 2.22 | -3.37 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NVO | CPH.TO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.82 | 0.59 | -1.41 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.05 | 1.14 | -1.09 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.19 | 0.13 | +0.06 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.47 | 0.07 | +0.40 |
Drawdowns
NVO vs. CPH.TO - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, smaller than the maximum CPH.TO drawdown of -98.29%. Use the drawdown chart below to compare losses from any high point for NVO and CPH.TO.
Loading charts...
Drawdown Indicators
| NVO | CPH.TO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -98.29% | +23.59% |
Max Drawdown (1Y)Largest decline over 1 year | -55.03% | -24.22% | -30.81% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -46.02% | -28.68% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | -46.02% | -28.68% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | -95.16% | +20.46% |
Current DrawdownCurrent decline from peak | -70.19% | -24.23% | -45.96% |
Average DrawdownAverage peak-to-trough decline | -17.77% | -65.74% | +47.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.21% | 11.22% | +25.99% |
Volatility
NVO vs. CPH.TO - Volatility Comparison
The current volatility for Novo Nordisk A/S (NVO) is 9.75%, while Cipher Pharmaceuticals Inc. (CPH.TO) has a volatility of 13.93%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than CPH.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | CPH.TO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.75% | 13.93% | -4.18% |
Volatility (6M)Calculated over the trailing 6-month period | 38.30% | 28.17% | +10.13% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.08% | 42.14% | +9.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.31% | 49.98% | -11.67% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.56% | 61.43% | -28.87% |
Dividends
NVO vs. CPH.TO - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 4.39%, while CPH.TO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CPH.TO Cipher Pharmaceuticals Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.39% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVO vs. CPH.TO - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Cipher Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. CPH.TO - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
CPH.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a gross profit of 8.35M and revenue of 12.30M. Therefore, the gross margin over that period was 67.9%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
CPH.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported an operating income of 5.50M and revenue of 12.30M, resulting in an operating margin of 44.7%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
CPH.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a net income of 6.06M and revenue of 12.30M, resulting in a net margin of 49.3%.
Frequently Asked Questions
NVO and CPH.TO have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for NVO and CPH.TO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer